Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies
IRST100.39
Phase 1 other active
Quick answer
Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies for Mesothelioma is a Phase 1 program (other) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- Mesothelioma
- Phase
- Phase 1
- Modality
- other
- Status
- active